In a new study published in Oncogenesis, Zhi Sheng and Rob Gourdie of the Fralin Biomedical Research Institute at VTC describe how two protein-targeting drugs – when combined with chemotherapy – yield synergistic cytotoxicity to treatment-resistant glioblastoma.